Labiana Health SA
BBME:LAB5.00
EUR
+0.20
(+4.17%)
ISIN
ES0105638003
Return %
Stock
S&P 500
1Y
22.51
14.20
3Y
339.34
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Manuel Ramos Ortega
- Full Time Employees
- 401
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Pozuelo de Alarcon Spain
- IPO Date
- Jun 24, 2022
- Website
- labiana.com
- Similar Companies
- Business
- Labiana Health SA is a Spain-based pharmaceutical and animal healthcare company that specializes in the development, manufacturing, and commercialization of human and veterinary pharmaceuticals, as well as providing end-to-end contract development and manufacturing organization (CDMO) and regulatory consulting services. Founded in 1958 and headquartered in Terrassa, Spain, the company trades on the BME Growth market under the ticker LAB and serves multinational pharmaceutical corporations, healthcare providers, veterinary distributors, and agricultural enterprises worldwide. The company conducts its operations through two core business segments: Animal Health and Human Health. Its Animal Health division focuses on the development, formulation, and production of proprietary and third-party veterinary medicines and biologicals, offering injectable solutions and suspensions; oral solutions, powders, and suspensions for livestock and companion animals; antiparasitics, antibiotics, analgesics, anti-inflammatories, and reproductive hormones; nutritional supplements, vitamins, and feed additives; and veterinary vaccines and biological treatments produced through specialized manufacturing assets. Its Human Health division provides comprehensive CDMO services and specialized healthcare products, offering formulation design and galenic development; analytical method development, validation, and stability testing; contract manufacturing of sterile liquid injectables, lyophilized vials, and aseptic fill-finish products; production of oral solid dosage forms, including tablets and hard capsules; manufacturing of liquid and semi-solid pharmaceutical preparations; secondary packaging, serialization, and batch release; and regulatory compliance, quality management, and technical advisory services through its Qualipharma consulting unit. Labiana Health maintains a global commercial reach, distributing proprietary pharmaceuticals and providing contract manufacturing solutions across Europe, Latin America, the Middle East, Africa, and Asia-Pacific, with market penetration spanning over 150 countries. The company operates multiple European Union Good Manufacturing Practice (EU-GMP) certified production facilities located in Terrassa and Corbera de Llobregat in Spain, as well as international biological manufacturing operations through Veterinarski Zavod Subotica in Serbia. In recent developments, Labiana Health has implemented comprehensive financial restructuring initiatives and syndicated debt refinancing packages to optimize its capital structure and enhance liquidity for ongoing manufacturing expansions; broadened its CDMO capacity with investments in sterile lyophilization, aseptic packaging, and automated high-throughput lines; expanded its global market authorizations with new regulatory approvals and commercial distribution alliances in Latin America and the Middle East; accelerated the development and registration of proprietary generic veterinary formulations; and integrated its consulting and technical services to provide turnkey pharmaceutical lifecycle solutions.